alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › anti-amyloid-immunotherapies

anti-amyloid-immunotherapies

4 studies tagged anti-amyloid-immunotherapies, dated 2023-06-02 to 2026-03-25. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. [Cerebral amyloid angiopathy-related inflammation and anti-amyloid immunotherapies] 2026-03-25
  2. Clinical Practice Recommendations of the Swiss Society for Neuroradiology: Neuroimaging Standards for Enrollment and Disease Monitoring in Anti-Amyloid Immunotherapies 2025-11-12
  3. Anti-amyloid immunotherapies for Alzheimer's disease: Administration, side effects, and overall framework 2025-05-24

Studies

4 studies carry this tag.

Date range

2023 to 2026

Top journals

  • Brain communications 1
  • Geriatric nursing (New York, N.Y.) 1
  • Neuro-degenerative diseases 1
  • Revue medicale suisse 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. [Cerebral amyloid angiopathy-related inflammation and anti-amyloid immunotherapies]

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Revue medicale suisse 2026-03-25 Treatments

    Cerebral amyloid angiopathy can be complicated by an inflammatory form known as CAA-ri (cerebral amyloid angiopathy-related inflammation), a rare but sometimes severe condition whose prognosis is improved by early diagnosis and treatment.

  2. Clinical Practice Recommendations of the Swiss Society for Neuroradiology: Neuroimaging Standards for Enrollment and Disease Monitoring in Anti-Amyloid Immunotherapies

    ✓ Peer-reviewed alzhub usefulness score 47 out of 100. Neuro-degenerative diseases 2025-11-12 Treatments

    This paper reviews the required imaging protocols and criteria for patient eligibility and discusses the key findings of ARIA-E and ARIA-H. These findings should be detected and interpreted by the practicing radiologist to ensure patient safety.

  3. Anti-amyloid immunotherapies for Alzheimer's disease: Administration, side effects, and overall framework

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Geriatric nursing (New York, N.Y.) 2025-05-24 Treatments

    Recently, the Food and Drug Administration (FDA) approved the use of aducanumab (Aduhelm), lecanemab (Leqembi), and donanemab (Kisunla) in patients with mild cognitive impairment (MCI) and early-stage dementia secondary to Alzheimer's disease (AD).

  4. Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer's disease

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Brain communications 2023-06-02 Treatments

    The clinical benefit associated with anti-amyloid immunotherapies, a new class of drugs for the treatment of Alzheimer's disease, is predicated on their ability to modify disease course by lowering brain amyloid levels.

All topic tags with their study counts